KellBenx | GenomeWeb

KellBenx

The company's technology relies on detecting a fetal cell-specific antibody in order to isolate and analyze the cells as early as six weeks gestation.

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

NEW YORK (GenomeWeb News) – Looking to enter the fast-growing non-invasive prenatal diagnostics space, CellScape is eyeing a second-half 2014 commercial launch of its test, which detects for fetal aneuploidies, and more importantly, genetic disorders that currently require invasive methods for de

NEW YORK (GenomeWeb News) – Start-up KellBenX is positioning itself as the David among the Goliaths of the non-invasive prenatal diagnostics space by building a test that it said can detect fetal chromosomal abnormalities beyond aneuploidies.

KellBenx Raises $2.5M

Funds from the round will be used to conduct a clinical trial and build its laboratory.

The Long Island, NY-based company will use the three biomarkers to develop blood-based tests to predict premature births.

Under the deal, KellBenz will use the antibodies to enrich fetal nucleated red blood cells "to perform chromosomal or genetic analysis to identify markers of potential disorders."

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.